Chengdu New Radiomedicine Technology Co.,Ltd. is an enterprise integrating research and development, innovation and industrialization of radiopharmaceuticals. It is mainly engaged in the development, production and sales of medical isotope diagnosis and therapeutic drugs, providing innovative technology services and scientific and technological consultation of radiopharmaceuticals, and developing foreign trade and technical cooperation of radiopharmaceuticals.

The company was established in 2016 by a group of scientists from nuclear industry system, including Mr. Jihui Qian, the former Director-General of the International Atomic Energy Agency (IAEA), Mr. Maoliang Li, the former Director of the Chengdu Isotope Application Research Institute of China Nuclear Power Research and Design Institute (NPIC) and Mr. Jiming Cai, the former deputy director of the Sichuan Atomic Energy Research Institute.

The company is located in Xihanggang Economic Development Zone, Shuangliu District, Chengdu, covering an area of 71 mu. It is creating a "Radiopharmaceutical Innovation and Industrialization Platform" in Shuangliu District, Chengdu. The company was recognized as a "Quasi Unicorn enterprise" In 2020, and "headquarters enterprise" and "high-tech enterprise" in 2021.

The company has more than 120 employees, including more than 70 R&D personnel, among them, there are 1 academician of the Chinese Academy of engineering, 2 provincial academic and technical leaders, and more than 10 researchers (professors); There are more than 10 PhDs and over 40 Ｍaster graduates. It is one of the most innovative technology-based enterprises in the radiopharmaceutical R&D industry in China.

The company has built an advanced radiopharmaceutical R&D laboratory, testing center, pilot workshop, production line and animal laboratory; own a number of "Class A, B and C unsealed radioactive material workplaces" approved by the Ministry of Ecology and Environment, and the "Experimental Animal Use License" issued by the Sichuan Provincial Laboratory Animal Management Committee. We Won the "Top 12 Biomedical Industry in the 6th China Innovation and Entrepreneurship Competition", "Sichuan Innovation and Entrepreneurship Competition Special Award" and other honors.

The company have carried out extensive scientific and technological cooperation with United States, Russia, Italy, Germany, Britain, Australia, France, Belgium and other countries. We have formed an extensive industry university research and application technology alliance with universities, nuclear science colleges, institutes, and nuclear medicine department of the class-III hospitals. The established engineering technology research center and the public service platform can provide a brand-new technical service platform for the innovative R & D and clinical application of radiopharmaceuticals.

Adhering to the concept of "forge ahead with innovation and pursuit of extraordinary quality", base on nuclear technology, we focuses on high quality, create an innovative and open radiopharmaceutical base, and casts a precise and efficient radiopharmaceutical brand.